Malignant pleural mesothelioma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 18, Issue SUPPL. 2, 2007, Pages

  Manegold, C ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b ESMO HEAD OFFICE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASBESTOS; CISPLATIN; DOXORUBICIN; MESOTHELIN; METHOTREXATE; OSTEOPONTIN; PEMETREXED; RALTITREXED;

ARTICLE; ASBESTOSIS; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CYTODIAGNOSIS; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LUNG RESECTION; MALIGNANT MESOTHELIOMA; MEDIASTINOSCOPY; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCUPATIONAL EXPOSURE; PHYSICAL EXAMINATION; PLEURA BIOPSY; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PLEURECTOMY; PLEURODESIS; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTOR; THORACOSCOPY; THORAX PAIN; THORAX RADIOGRAPHY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MESOTHELIOMA; NEOPLASM STAGING; PLEURAL NEOPLASMS; RISK ASSESSMENT;

EID: 47249128245     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm027     Document Type: Article

References (11)

1. Peto J, Decarli A, La Vecchia C et al. The European mesothelioma epidemic. Br J Cancer 1999; 86: 1970-1971.
2. Pelucchi C, Malvezzi M, La Vecchia C et al. The mesothelioma epidemic in Western Europe: An update. Br J Cancer 2004; 90: 1022-1024.
3. Robinson BW, Creaney J, Lake R et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003; 362: 1612-1616.
4. Sugarbaker DJ, Flores RM, Jaklitsch MT et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients. J Thorac Cardiovasc Surg 1999; 17: 54-63.
5. Waller DA. The role of surgery in diagnosis and treatment of malignant pleural mesothelioma. Curr Opin Oncol 2003; 15: 139-143.
6. Weder W, Kestenholz P, Taverna C et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 2004; 22: 3451-3457.
7. Senan S. Indications and limitations of radiotherapy in malignant pleural mesothelioma. Curr Opin Oncol 2003; 15: 144-147.
8. Tomek S, Emri S, Krejcy E, Manegold C. Chemotherapy for malignant pleural mesothelioma: Past results and recent developments. Br J Cancer 2003; 88: 167-174.
9. Steele JP, Klabatsa A. Chemotherapy options and new advances in malignant mesothelioma. Ann Oncol 2005; 16: 345-351.
10. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patints with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644.
11. van Meerbeeck JP, Gaafar R, Manegold C et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005; 23: 6881-6889.